Minimally invasive surgical modalities in the management of localized prostate cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 6, 2008, Pages 957-966

  Jamal, Karim ^a   Patel, Pareeta ^a   Sooriakumaran, Prasanna ^a  

^a KINGSTON HOSPITAL   (United Kingdom)

Author keywords

Brachytherapy; Cryotherapy; High intensity focused ultrasound; Laparoscopic radical prostatectomy; Localized prostate cancer; Minimally invasive therapy; Robotic assisted laparoscopic radical prostatectomy

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; CESIUM; CESIUM 131; GADOLINIUM; GONADORELIN DERIVATIVE; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

BLADDER NECK STENOSIS; BRACHYTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CRYOSURGERY; DISEASE FREE SURVIVAL; ERECTILE DYSFUNCTION; HALF LIFE TIME; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LAPAROSCOPIC SURGERY; LENGTH OF STAY; MICTURITION DISORDER; MINIMALLY INVASIVE SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPERATION DURATION; OVERALL SURVIVAL; PATIENT SELECTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; ROBOTICS; SURGICAL TECHNIQUE; SURGICAL TRAINING; SURVIVAL RATE; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL INCISION OF THE PROSTATE; UNSPECIFIED SIDE EFFECT; URETHRA STRICTURE; URINE INCONTINENCE; URINE RETENTION; LAPAROSCOPY; MALE; METHODOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

BRACHYTHERAPY; CRYOSURGERY; HUMANS; LAPAROSCOPY; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROBOTICS; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TREATMENT OUTCOME; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 47249141370     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.6.957     Document Type: Review

References (67)

1. Jemal A, Siegal R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics. CA Cancer J. Clin. 57(1), 43-66 (2007).
2. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol. Oncol. 24(5), 396-402 (2006).
3. Blana, A, Murat FJ, Walter B et al. First analysis of the long term results with trans-rectal HIFU in patients with localised prostate cancer. Eur Urol. (2008) (Epub ahead of print).
4. Gould RS. Total-cryosurgery of the prostate versus standard cryosurgery versus radical prostatectomy; comparison of early results and the role of trans-urethral resection in cryosurgery. J. Urol. 162(5), 1653-1657 (1999).
5. Lynn LG, Putnam TJ. Histological and cerebral lesions produced by focused ultrasound. Ann. J. Pathol. 22(11), 437-441 (1944).
6. Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high intensity focussed ultrasound on human prostite cancer in vivo. Cance Res. 55(15), 3346-1351 (1995).
7. Kennedy JE, Ter Haar GR, Cranston D. High intensity field ultrasound: surgery of the future? Br J Radiol. 76(909), 590-599 (2003).
8. Chapelon JY, Margonari J, Vernier F, Gorry F, Ecochard R, Gelet A. In vivo effects of high intensity field ultrasound on prostate adenocarcinoma Dunning R3327. Cancer Res. 52(22), 6353-6357 (1992).
9. Rouviere O, Lyonnet D, Raudrant A et al. MRI appearance of prostate following trans-rectal HIFU ablation of localised prostate cancer. Eur Urol. 40(3), 265-274 (2001).
10. Rebillard X, Davin JL, Soulie M. Treatment by HIFU of prostate cancer: a survey of literature and treatment indications. Prog. Urol. 13(6), 1428-1456 (2003).
11. Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B. Morbidity associated with repeated trans-rectal high intensity field ultrasound treatment of localised prostate cancer. World J. Urol. 24(5), 585-590 (2006).
12. Lee HM, Hong JH, Choi HY. High intensity field ultrasound-therapy for clinically localised prostate cancer. Prostate Cancer Prostatic Dis. 9(4), 439-443 (2006).
13. No authors listed. Consensus statement: guidelines for PSA following radiation therapy. American Society of Therapeutic Radiology and Oncology Consensus panel. Int. J. Radiat. Oncol. Biol. Phys. 37, 1035-1041 (1997).
14. Poissonnier L, Chapelon JY, Rouviere O et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol. 51(2), 381-387 (2007).
15. Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A. Treatment of localised prostate cancer using high-intensity field ultrasound. BJU Int. 97(1), 56-61 (2006).
16. Murat FJ, Poissonnier L, Pasticier G, Geler A. High intensity field ultrasound (HIFU) for prostate cancer. Cancer Control 14(3), 244-249 (2007).
17. Thuroff S, Chaussy C, Vallancien G et al. High-intensity focused ultrasound and localised prostate cancer: efficacy results from the European multicentric study. J. Endourol. 17(8), 673-677 (2003).
18. Chaussy CG, Thuroff S. High-intensity focused ultrasound in localised prostate cancer. J. Endourol. 14(3), 293-299 (2000).
19. Chaussy C, Thuroff S. The stats of high-intensity focused ultrasound in the treatment of localised prostate cancer and the impact of a cumbined resection. Curr. Urol. Rep. 4(3), 248-252 (2003).
20. Paparel P, Curiel L, Chesnais S, Ecochard R, Chapelon JY, Gelet A. Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma. BJU Int. 95(6), 881-1885 (2005).
21. de Senneville BD, Mougenot C, Moonen CT. Real-time methods for treatment of mobile organs by MRI-controlled high-intensity focused ultrasound. Magn. Reson. Med. 57(2), 319-330 (2007).
22. Gonder MJ, Soanes WA, Shulman S. Cryosurgical treatment of the prostate. Invest. Urol. 3(4), 372-378 (1966).
23. Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology 37(3), 171-186 (1998).
24. Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int. 95(9), 1187-1191 (2005).
25. Porter MP, Ahaghotu CA, Loening SA, See WA. Disease free and overall survival after cryosurgical monotherapy for clinical stages B and C carcinoma of the prostate: a 20 year follow up. J. Urol. 158(4), 1466-1469 (1997).
26. Shelley M, Wilt TJ, Coles B, Mason MD. Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev. 18(3), CD005010 (2007).
27. Wong WS, Chinn DO, Chinn M, Chinn J, Tom WL. Cryosurgery as a treatment for prostate carcinoma: results and complications. Cancer 79(5), 963-974 (1997).
28. Chin JL, Lim D, Abdelhady M. A review of primary and salvage cryoablation for prostate cancer. Cancer Control 14(3), 1231-237 (2007).
29. Robinson JW, Donnelly BJ, Saliken JC et al. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology 60, 12-18 (2002).
30. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localised prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 54(4), 1063-1068 (2002).
31. Onik G, Narayan P, Vaughan D, Dineen M, Brunelle R. Focal nerve sparing cryosurgery for treatment of primary prostate cancer; a new approach to serving potency. Urology 60(1), 109-114 (2002).
32. Long JP, Fallick ML, LaRock DR, Rand W. Preliminary outcomes following cryosurgical ablation of the prostate in p;tients with clinically localised prostate cancer. J. Urol. 159(2), 477-484 (1998).
33. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7 year outcomes in the primary treatment of prostate cancer. Urology 60(2 Suppl. 1), 3-11 (2002).
34. Cohen JK, Miller RJ, Rooker GM, Shuman BA. Cryosurgical ablation of the prostate: two-year prostate specific antigen and biopsy results. Urology 47(3), 395-401 (1996).
35. Donnelly BJ, Saliken JC, Ernst DS et al. Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology 60(4), 645-649 (2002).
36. Coogen CL, McKiel CF. Percutaneous cryoablation of the prostate: preliminary results after 95 procedures. J. Urol. 154(5), 813-817 (1995).
37. Aus G, Pileblad E, Hugosson J. Cryosurgical ablation of the prostate: 5-year follow-up of a prospective study. Eur. Urol. 42(2), 133-138 (2002).
38. Schuessler WW, Schulam PG, Clayman RV, Kavoussi LR. Laparascopic radical prostatectomy; initial short term experience. Urology 50(6), 854-857 (1997).
39. Guillonneau B, Cathelineau X, Barret E, Rozet F, Vallancien G. Laparocopic radical prostatectomy technical and early oncological assessment of 40 operations. Eur. Urol. 36(1), 14-20 (1999).
40. Tooher R, Swindle P, Woo H, Miller J, Maddern G. Laparoscopic radical prostatectomy for localised prostate cancer. A systematic review of comparative studies. J. Urol. 175(6), 2011-2017 (2006).
41. Ficarra V, Cavalleri S, Novara G, Aragona M, Artibani W. Evidence from robotic assisted laparoscopic radical prostatectomy: a systematic review. Eur. Urol. 51(1), 45-55 (2007)
42. Rassweiler J, Seemann O, Schulze M, Teber D, Hatzinger M, Frede T. Laparoscopic versus open radical prostatectomy. A comparative study at a single institution. J. Urol. 169(5), 1689-1693 (2003).
43. Rogers CG, Su LM, Link RE, Sullivan W, Wagner A, Pavlovich CP. Age stratified functional outcomes after laparoscopic radical prostatectomy. J. Urol. 176(6 Pt 1), 2248-2252 (2006).
44. Patel VR, Thaly R, Shah K. Robotic radical prostatectomy: outcomes of 500 cases. BJU Int. 99(5), 1109-1112 (2007)
45. Tewari A, Srivasatava A, Menon M. A prospective comparison of radical retropubic and robotic-assisted radical prostatectomy: experience in one institution. BJU Int. 92(3), 205-210 (2003).
46. Patel VR, Chammas MF, Shah S. Robotic assisted laparoscopic radical prostatectomy; a review of the current state of affairs. Int. J. Clin. Pract. 61(2), 309-314 (2007).
47. Hakimi AA, Feder M, Ghavamian R. Minimally invasive approaches to prostate cancer: a review of the current literature. J. Urol. 4(3), 130-137 (2007).
48. Alhering TE, Skarecky D, Lee D, Clayman RV. Successful transfer of open surgical skills to a laparoscopic environment using robotic interface: initial experience with laparoscopic radical prostatectomy. J. Urol. 170(5), 1738-1741 (2003).
49. Gianino MM, Galzerano M, Tizzani A, Gontero P. Critical issues in current comparative and cost analyses between retropubic and robotic radical prostatectomy. BJU Int. 101 (1) 2-3, (2008).
50. Pasteau O, Degrais P. De l'emploi du radium dans le traitement des cancers de la prostate. J. D'urologie Medicale et Chirurgicale 4, 341-366 (1919).
51. Whihitmore WF Jr, Hilaris B, Grabstald H. Retropubic implantation of iodine 125 in the treatment of prostate cancer. J. Urol. 167(2 Pt 2), 981-983 (2002).
52. Grimm PD, Blasko JC, Ragde H. Ultrasound guided trans-perineal implantation of iodine-125 and Palladium-103 in the treatment of early stage prostate cancer. Technical concepts in planning, operative technique and evaluation. Urol. Clin. North Am. 2, 113-125 (1994).
53. Stock RG, Stone NN, Wesson MF, DeWyngaert JK. A modified technique allowing interactive ultrasound guided three-dimensional trans-perineal prostate implantation. Int. J. Radiat. Oncol. Biol. Phys. 32(1), 219-225 (1995).
54. Zelefsky MJ, Yamada Y, Cohen G et al. Post implantation dosimetric analysis of permanent trans-perineal prostate implantation: improved dose distributions with an intraoperative computer optimising conformal planning technique. Int. J. Radiat. Oncol. Biol. Phys. 48(2), 601-608 (2000).
55. Henderson A, Langley SEM, Laing R. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective observational study. Clin. Oncol. 15(6), 318-321 (2003).
56. Wallner K, Merrick G, True L, Cavanagh W, Simpson C, Butler W. Iodine-125 versus Palladium-103 for low risk prostate cancer: morbidity outcomes from a prospective randomised multi-center trial. Cancer J. 8(1), 67-73 (2002).
57. Heysek RV, Gwede CK, Torres-Roca J et al. A Dosimetric analysis of unstranded seeds versus customised seeds in trans-perineal intersitial permanent prostate seed brachytherapy. Brachytherapy 5(4), 244-250 (2006).
58. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10 year biochemical control of prostate cancer with Iodine-125 brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 51(1), 31-40 (2001).
59. Blasko JC, Grimm PD, Sylvester JE, Cavanagh W. The role of external beam radiotherapy with iodine-125 and Palladium-103 brachytherapy for prostate cancer. Radiother. Oncol. 57(3), 273-278 (2000).
60. Vicini FA, Martinez A, Hanks G et al. An interinstitutional study and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow up. Cancer 95(10), 2126-2135 (2002).
61. Cheung R, Tucker SL, Lee AL et al. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 61(1), 14-19 (2005).
62. Datolli M, Wallner K, True L, Cash J, Sbrace R. Long term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer having intermediate and high risk features. Cancer 110(3), 551-556 (2007).
63. Langley SEM, Laing RW. Iodine seed prostate brachytherapy: an alternative first line choice to prostate cancer. Prostate Cancer Prostatic Dis. 7(3), 201-207 (2004).
64. Mabjeesh NJ, Chen J, Stenger A, Matzkin H. Preimplant predictive factors of urinary retention after iodine-125 prostate brachytherapy. Urology 7(3), 548-553 (2007).
65. Potter L, Torre T, Feam PA, Leibel SA, Kattan MW. Potency after permanent prostate brachytherapy for localised prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 50(5), 1235-1242 (2001).
66. Merrick GS, Butler WM. Rectal function following prostate brachytherapy. W. V. Med. J. 100(1), 18-20 (2004).
67. Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 48(1), 119-124 (2000).